These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 17369837)

  • 1. CD8(+) T-cell responses to adeno-associated virus capsid in humans.
    Mingozzi F; Maus MV; Hui DJ; Sabatino DE; Murphy SL; Rasko JE; Ragni MV; Manno CS; Sommer J; Jiang H; Pierce GF; Ertl HC; High KA
    Nat Med; 2007 Apr; 13(4):419-22. PubMed ID: 17369837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of mouse AAV capsid-specific CD8+ T cell epitopes.
    Sabatino DE; Mingozzi F; Hui DJ; Chen H; Colosi P; Ertl HC; High KA
    Mol Ther; 2005 Dec; 12(6):1023-33. PubMed ID: 16263332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
    Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
    Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid.
    Vandenberghe LH; Wang L; Somanathan S; Zhi Y; Figueredo J; Calcedo R; Sanmiguel J; Desai RA; Chen CS; Johnston J; Grant RL; Gao G; Wilson JM
    Nat Med; 2006 Aug; 12(8):967-71. PubMed ID: 16845388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates.
    Li H; Lasaro MO; Jia B; Lin SW; Haut LH; High KA; Ertl HC
    Mol Ther; 2011 Nov; 19(11):2021-30. PubMed ID: 21587208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses to AAV in clinical trials.
    Mingozzi F; High KA
    Curr Gene Ther; 2007 Oct; 7(5):316-24. PubMed ID: 17979678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors.
    Sarukhan A; Camugli S; Gjata B; von Boehmer H; Danos O; Jooss K
    J Virol; 2001 Jan; 75(1):269-77. PubMed ID: 11119597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses to AAV in clinical trials.
    Mingozzi F; High KA
    Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets.
    Wang L; Figueredo J; Calcedo R; Lin J; Wilson JM
    Hum Gene Ther; 2007 Mar; 18(3):185-94. PubMed ID: 17324107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of CpG Sequences on Capsid-Specific CD8
    Xiang Z; Kurupati RK; Li Y; Kuranda K; Zhou X; Mingozzi F; High KA; Ertl HCJ
    Mol Ther; 2020 Mar; 28(3):771-783. PubMed ID: 31839483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.
    Yuasa K; Yoshimura M; Urasawa N; Ohshima S; Howell JM; Nakamura A; Hijikata T; Miyagoe-Suzuki Y; Takeda S
    Gene Ther; 2007 Sep; 14(17):1249-60. PubMed ID: 17581597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.
    Martino AT; Basner-Tschakarjan E; Markusic DM; Finn JD; Hinderer C; Zhou S; Ostrov DA; Srivastava A; Ertl HC; Terhorst C; High KA; Mingozzi F; Herzog RW
    Blood; 2013 Mar; 121(12):2224-33. PubMed ID: 23325831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
    Zaiss AK; Muruve DA
    Gene Ther; 2008 Jun; 15(11):808-16. PubMed ID: 18385765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T Cell-Mediated Immune Responses to AAV and AAV Vectors.
    Ertl HCJ
    Front Immunol; 2021; 12():666666. PubMed ID: 33927727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies.
    Huttner NA; Girod A; Perabo L; Edbauer D; Kleinschmidt JA; Büning H; Hallek M
    Gene Ther; 2003 Dec; 10(26):2139-47. PubMed ID: 14625569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors.
    Veron P; Leborgne C; Monteilhet V; Boutin S; Martin S; Moullier P; Masurier C
    J Immunol; 2012 Jun; 188(12):6418-24. PubMed ID: 22593612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells.
    Mingozzi F; Meulenberg JJ; Hui DJ; Basner-Tschakarjan E; Hasbrouck NC; Edmonson SA; Hutnick NA; Betts MR; Kastelein JJ; Stroes ES; High KA
    Blood; 2009 Sep; 114(10):2077-86. PubMed ID: 19506302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific adeno-associated virus serotypes facilitate efficient gene transfer into human and non-human primate mesenchymal stromal cells.
    Chng K; Larsen SR; Zhou S; Wright JF; Martiniello-Wilks R; Rasko JE
    J Gene Med; 2007 Jan; 9(1):22-32. PubMed ID: 17154338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adeno-associated virus serotypes: vector toolkit for human gene therapy.
    Wu Z; Asokan A; Samulski RJ
    Mol Ther; 2006 Sep; 14(3):316-27. PubMed ID: 16824801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome.
    Wu TL; Li H; Faust SM; Chi E; Zhou S; Wright F; High KA; Ertl HC
    Mol Ther; 2014 Jan; 22(1):42-51. PubMed ID: 24077034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.